Product Description
Mechanisms of Action: NAMPT Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: TopoTarget A/S
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: T-Cell Cutaneous Lymphoma|T-Cell Peripheral Lymphoma|Melanoma|Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia|Lymphoma, Non-Hodgkin|Mycosis Fungoides|Lymphoma, B-Cell
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| APO866 for CTCL | P2 |
Completed |
Mycosis Fungoides|Lymphoma, Non-Hodgkin|T-Cell Cutaneous Lymphoma|Lymphoma, B-Cell |
2011-09-22 |
2025-05-23 |
Treatments |
|
| AP3001 | P2 |
Completed |
T-Cell Cutaneous Lymphoma|T-Cell Peripheral Lymphoma |
2011-01-01 |
2023-12-14 |
Primary Endpoints |
|
| 2006-000910-19 | P2 |
Completed |
Melanoma |
2009-03-24 |
2022-03-12 |
Treatments |
|
| 2006-002850-31 | P2 |
Completed |
Chronic Lymphoid Leukemia |
2008-02-02 |
2022-03-12 |
Treatments |
|
| AP3003 | P2 |
Completed |
Melanoma |
2008-02-01 |
2023-12-14 |
Primary Endpoints|Treatments |
|
| AP3005 | P2 |
Completed |
Lymphocytic Chronic B-Cell Leukemia|Chronic Lymphoid Leukemia |
2008-02-01 |
2023-12-14 |
Primary Endpoints |